Change of Adviser

RNS Number : 1484R

SkinBioTherapeutics PLC

26 June 2020

 

26 June 2020

SkinBioTherapeutics plc

Change of Adviser

SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, announces that Cenkos Securities plc has been appointed with immediate effect as the Company's Nominated Adviser and Sole Broker.

SkinBioTherapeutics plc	Tel: [phone]
Stuart Ashman, CEO
Doug Quinn, CFO
Cenkos Securities plc (Nominated Adviser & Broker)	Tel: [phone]
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
Instinctif Partners	Tel: [phone]
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis	[e-mail]

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company has demonstrated, through scientific testing, that the SkinBiotix® platform can improve the barrier effect of skin models, protect from infection and repair wounds. Proof of principle studies have also shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. The technology achieved positive results in clinical studies in human volunteers in early 2019.

The Company listed on AIM in April 2017 and is based in Manchester, UK.  For more information, visit:  www.skinbiotherapeutics.com   . 

 

END

 

 

APPBCGDLGXDDGGU